-transparent.png){kind=logo}
Stereotyped behavior and striatal c-fos levels induced by chronic treatment with the D1 dopamine antagonist SCH 23390 have been investigated in rats which received subsequent subacute dopamine agonist treatment. SCH 23390 treatment (0.5 mg/kg/day) for 21 days increased both apomorphine-induced orofacial stereotypies and striatal c-fos levels. Treatment with the D1 dopamine agonist SKF 38393 (10 mg/kg/day) and the combination of SKF 38393 with the D2 dopamine agonist quinpirole (1 mg/kg/day), for 5 consecutive days, attenuated apomorphine-induced stereotypies without changing c-fos levels in rats previously treated with SCH 23390. These findings suggest that SCH 23390-induced behavioral supersensitivity and the increased striatal c-fos levels are concomitant but unrelated phenomena.
J E Muñoz, and
C Marín, and
E Tolosa
June 1996,
Synapse (New York, N.Y.),
J E Muñoz, and
C Marín, and
E Tolosa
July 1988,
Brain research,
J E Muñoz, and
C Marín, and
E Tolosa
March 1996,
Pharmacology, biochemistry, and behavior,
J E Muñoz, and
C Marín, and
E Tolosa
January 1989,
Journal of receptor research,
J E Muñoz, and
C Marín, and
E Tolosa
March 1996,
Neuropharmacology,
J E Muñoz, and
C Marín, and
E Tolosa
August 1997,
Neuropharmacology,
J E Muñoz, and
C Marín, and
E Tolosa
January 1986,
Psychopharmacology,
J E Muñoz, and
C Marín, and
E Tolosa
November 1985,
European journal of pharmacology,
J E Muñoz, and
C Marín, and
E Tolosa
November 1983,
Neuropharmacology,
J E Muñoz, and
C Marín, and
E Tolosa
April 1990,
European journal of pharmacology,
